Categories: Automobile

2025 Kia Telluride ranks number one in its segment in J.D. Power 2025 U.S. Initial Quality Study (IQS)

Kia’s Award-Winning Three-Row SUV Earns Top Spot in Upper Midsize SUV Segment

- Advertisement -
  • 2025 Telluride named the Upper Midsize SUV segment winner in the J.D. Power 2025 IQS
  • Award highlights Telluride’s strong performance in quality, and customer satisfaction 

The 2025 Kia Telluride has earned the top spot in the J.D. Power 2025 U.S. Initial Quality Study (IQS) in the Upper Midsize SUV segment. Recognized for having the fewest quality issues over the first 90 days of ownership, the Telluride assembled at Kia’s West Point, GA plant is known for its spacious interior, advanced features, and bold design. The J.D. Power IQS award comes on the heels of sustained sales success for both the Telluride and the Kia model lineup, at-large. Year-over-year sales of Telluride have increased nearly 17 percent, while Kia vehicle sales are up more than 10 percent.

- Advertisement -

“Our world-class vehicles deliver the quality, reliability and technology that consumers are looking for,” said Steven Center, COO & EVP, Kia America. “This J.D. Power IQS award demonstrates Kia’s dedication to engineering high-quality vehicles designed to fulfill the needs of the entire family.”

- Advertisement -

The annual report analyzed responses from 92,694 respondents with regards to 182 rank eligible vehicle models across 25 segments. Vehicles were evaluated on driving experience, engine and transmission performance, and a broad range of quality issues reported by vehicle owners. 

- Advertisement -
TheNews Market

Recent Posts

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast,…

3 hours ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

7 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

7 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

7 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

7 hours ago